Edgewise Therapeutics, Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-25

Reporting Person: Novo Holdings A/S (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
SERIES B-1 CONVERTIBLE PREFERRED STOCK	$		COMMON STOCK (2359440)		Direct
SERIES B-2 CONVERTIBLE PREFERRED STOCK	$		COMMON STOCK (1952439)		Direct
SERIES C CONVERTIBLE PREFERRED STOCK	$		COMMON STOCK (650328)		Direct

Footnotes

F1: Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock will convert automatically into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.